ES2729111T3 - Método para la preparación de adyuvante de hidroxifosfato de aluminio - Google Patents

Método para la preparación de adyuvante de hidroxifosfato de aluminio Download PDF

Info

Publication number
ES2729111T3
ES2729111T3 ES12851733T ES12851733T ES2729111T3 ES 2729111 T3 ES2729111 T3 ES 2729111T3 ES 12851733 T ES12851733 T ES 12851733T ES 12851733 T ES12851733 T ES 12851733T ES 2729111 T3 ES2729111 T3 ES 2729111T3
Authority
ES
Spain
Prior art keywords
aluminum
phosphate
solution
buffer
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12851733T
Other languages
English (en)
Spanish (es)
Inventor
David Thiriot
Patrick Ahl
Jayme Cannon
Gabriel Lobel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of ES2729111T3 publication Critical patent/ES2729111T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00—Phosphorus; Compounds thereof
    • C01B25/16—Oxyacids of phosphorus; Salts thereof
    • C01B25/26—Phosphates
    • C01B25/36—Aluminium phosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ES12851733T 2011-11-23 2012-11-19 Método para la preparación de adyuvante de hidroxifosfato de aluminio Active ES2729111T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161563213P 2011-11-23 2011-11-23
PCT/US2012/065741 WO2013078102A1 (en) 2011-11-23 2012-11-19 Method for preparation of aluminum hydroxyphosphate adjuvant

Publications (1)

Publication Number Publication Date
ES2729111T3 true ES2729111T3 (es) 2019-10-30

Family

ID=48470220

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12851733T Active ES2729111T3 (es) 2011-11-23 2012-11-19 Método para la preparación de adyuvante de hidroxifosfato de aluminio

Country Status (6)

Country Link
US (1) US9573811B2 (enExample)
EP (1) EP2782594B1 (enExample)
KR (1) KR102032002B1 (enExample)
ES (1) ES2729111T3 (enExample)
IN (1) IN2014CN03391A (enExample)
WO (1) WO2013078102A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107921119B (zh) * 2015-06-12 2021-10-08 生物E有限公司 制备应用于疫苗制剂的磷酸铝凝胶的方法
EP3528827A4 (en) 2016-10-21 2020-11-04 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
KR20200077538A (ko) * 2017-10-25 2020-06-30 머크 샤프 앤드 돔 코포레이션 아주반트 첨가된 백신
BR112020015308A8 (pt) 2018-01-29 2023-02-07 Merck Sharp & Dohme Proteínas f de rsv estabilizadas e usos das mesmas
EP3556728A1 (en) 2018-04-16 2019-10-23 Croda Denmark A/S Organically modified mineral micro-particles, methods of preparing the same and uses thereof
WO2019225667A1 (ja) * 2018-05-23 2019-11-28 一般財団法人阪大微生物病研究会 リン酸アルミニウム化合物
CA3112837A1 (en) * 2018-10-19 2020-04-23 Translate Bio, Inc. Pumpless encapsulation of messenger rna
JP7644933B2 (ja) 2019-04-11 2025-03-13 シァメン・イノヴァックス・バイオテック・カンパニー・リミテッド ゾレドロン酸亜鉛マイクロ／ナノ粒子アジュバントの作製及びワクチンアジュバントとしてのその使用
CA3142321A1 (en) 2019-05-30 2020-12-03 Xiamen University Preparation of zinc risedronate micro/nano adjuvant and use thereof as vaccine adjuvant
CN113666404B (zh) * 2021-09-23 2023-07-28 北京智飞绿竹生物制药有限公司 一种适合规模化生产的高浓度纳米级氢氧化铝佐剂配制方法
KR20230047827A (ko) * 2021-10-01 2023-04-10 에스케이바이오사이언스(주) 향상된 효능을 갖는 알루미늄계 애주번트를 제조하는 방법
WO2024205322A1 (ko) * 2023-03-31 2024-10-03 에스케이바이오사이언스(주) 향상된 효능을 갖는 알루미늄계 애주번트를 제조하는 방법
KR20260008117A (ko) 2023-05-08 2026-01-15 머크 샤프 앤드 돔 엘엘씨 노로바이러스 vp1 항원을 코딩하는 폴리뉴클레오티드 및 그의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2181426B1 (enExample) 1972-04-06 1974-12-20 Pasteur Institut
US4016252A (en) 1972-04-06 1977-04-05 Institut Pasteur Calcium phosphate gel for adsorbing vaccines
US8540955B2 (en) * 2007-07-10 2013-09-24 Wyeth Llc Process for producing aluminum phosphate
EP2430040A1 (en) * 2009-05-11 2012-03-21 Novartis AG Antigen purification process for pertactin antigen
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition

Also Published As

Publication number Publication date
IN2014CN03391A (enExample) 2015-07-03
KR20140100530A (ko) 2014-08-14
KR102032002B1 (ko) 2019-10-14
EP2782594A1 (en) 2014-10-01
EP2782594A4 (en) 2015-07-29
EP2782594B1 (en) 2019-04-17
WO2013078102A1 (en) 2013-05-30
US20140314653A1 (en) 2014-10-23
US9573811B2 (en) 2017-02-21

Similar Documents

Publication Publication Date Title
ES2729111T3 (es) Método para la preparación de adyuvante de hidroxifosfato de aluminio
ES2650740T3 (es) Composición de vacuna con unas nanopartículas de hidróxido de aluminio
US20250114307A1 (en) Dry powder composition comprising long-chain rna
Karimy et al. Cerebrospinal fluid hypersecretion in pediatric hydrocephalus
ES2634699T3 (es) Métodos para preparar composiciones nanocristalinas usando acústica enfocada
EP3062900A1 (en) Drying techniques for microfluidic and other systems
ES3025099T3 (en) Apparatus and method for mixing small liquid volumes, and use of the apparatus
JP7795235B2 (ja) Ａｌ－Ｍｎ複合ナノ結晶及びその製造方法と使用
US8697133B2 (en) Slow release compositions
US20200164338A1 (en) Continuous manufacture of guidance molecule drug conjugates
CN202168952U (zh) 一种全自动无菌配药设备
CN105395483A (zh) 一种可还原降解超支化聚合物纳米胶束及其制备方法
CN106430141A (zh) 纳米锶羟基磷灰石的制备方法
BR112020001058A2 (pt) remoção de medicamento dissociado após acoplamento de conjugado a anticorpo e medicamento
CN107921119B (zh) 制备应用于疫苗制剂的磷酸铝凝胶的方法
CN112295476A (zh) 静态微混合芯片装置、磷酸铝佐剂的制备方法及其应用
JP2024119170A (ja) 医薬組成物、医薬組成物の製造方法および医薬組成物の製造装置
EA042612B1 (ru) Вакцинная композиция и способ ее получения
WO2025244961A1 (en) Processes for making stable nanoemulsion adjuvants
de São João Continuous Synthesis of Hydroxyapatite Nanoparticles in a Planar Oscillatory Flow Reactor: Effect of Surfactant Concentration
Connell Silica nanoparticles as adjuvants for novel vaccines: a combined immunological, simulation and physical characterisation study
CN103432132B (zh) 甲磺酸普立地诺双氯芬酸钠注射液及其制备方法
HK40116872A (zh) 用於混合小液体体积的设备和方法以及该设备的用途
EP2424876A1 (en) Protein crystallisation
WO2011145914A1 (es) La lidocaína como transformadora y productora de complejos de fármacos trasformados aplicados en nanodosis mediante implantes por inyección como dispositivos de liberación prolongada